長陽科技(688299.SH):首條幹法隔膜設備已投產,並取得了比亞迪相應訂單,暫未有產品送樣特斯拉認證
格隆匯6月1日丨有投資者向長陽科技(688299.SH)提問,“特斯拉海外首個儲能超級工廠落户上海:年產一萬台,明年二季度投產.公司已有產品有沒有準備送樣特斯拉驗證”
長陽科技回覆稱,儲能市場是公司隔膜重要的應用市場之一。公司首條幹法隔膜設備已投產,已獲得國內主流儲能客户認證,並取得了比亞迪相應訂單,公司暫未有產品送樣特斯拉認證。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.